Nuclear factor-KB polypeptide inhibitor 3 and application thereof

A polypeptide inhibitor, -KB technology, applied in the direction of peptides, anti-inflammatory agents, peptide/protein components, etc., to achieve the effect of preventing or treating rheumatoid arthritis

Inactive Publication Date: 2014-05-07
NANTONG CHENGXIN AMINO ACID
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

2. Steroid hormones. Hormones are very good analgesic and anti-inflammatory drugs, but long-term use alone cannot improve the condition, but bring many side effects. Steroids can be used as a transitional second-line slow-acting drug before it takes effect, but the dosage should be limited. small, not too long
However, there are no well-developed nuclear factor-KB peptide inhibitors available for the treatment of RA

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0015] The effect of nuclear factor-KB polypeptide inhibitor 3 on the swelling degree of the left paw of mice with collagen type arthritis. Compared with each other, there were extremely significant differences (P<0.01), and the experimental results were statistically significant. The effect of nuclear factor-KB polypeptide inhibitor 3 on the swelling degree of the right paw of mice with collagen type arthritis. There were extremely significant differences (P<0.01), and the experimental results were statistically significant. The effect of nuclear factor-KB polypeptide inhibitor 3 on the clinical scores of mice with collagen arthritis, the scores of limbs in the low, medium and high doses of polypeptide 3 groups were significantly lower than those in the model control group (P<0.01), which was extremely significant compared with the model control group The difference was found to be statistically significant. The effect of nuclear factor-KB polypeptide inhibitor 3 on the bod...

Embodiment 2

[0021] The effect of nuclear factor-KB polypeptide inhibitor 3 on the paw swelling degree of rats with primary arthritis, the diameter of the left rear ankle in the positive control group, low, medium and high dose groups of nuclear factor-KB polypeptide inhibitor 3 Compared with the model group, there was a very significant difference (P<0.01); the diameter of the left rear ankle of the nuclear factor-KB polypeptide inhibitor 3 low, middle and high dose groups was significantly different from that of the model group (P<0.05 ), the experimental results are statistically significant. The effect of nuclear factor-KB polypeptide inhibitor 3 on the paw swelling degree of rats with secondary arthritis, the diameter of right hind ankle in the positive control group, nuclear factor-KB polypeptide inhibitor 3 low, medium and high dose groups Compared with the model group, there was a significant difference (P<0.05). The effect of nuclear factor-KB polypeptide inhibitor 3 on the clini...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a nuclear factor-KB polypeptide inhibitor 3 and application thereof, relates to the field of medicines and in particular relates to a polypeptide with effects of inhibiting nuclear factor-KB and preventing and treating rheumatoid arthritis. The sequence of TRILAQHRLYINNSGGE is a brand new sequence. The nuclear factor-KB polypeptide inhibitor 3 has the beneficial effects that the nuclear factor-KB polypeptide inhibitor 3 can be used for treating the rheumatoid arthritis and has the potential new drug development value.

Description

Technical field: [0001] The invention relates to the field of medicines, in particular to nuclear factor-KB polypeptide inhibitors for preventing and treating or preventing rheumatoid arthritis. Background technique: [0002] Rheumatoid arthritis (RA) is the most common clinical inflammatory joint disease and one of the main disabling factors. It is about 0.5%-1.0% in the world, and the incidence of RA is about 0.4% in my country. RA can occur at any age, and the incidence rate increases with age. The high-incidence age of women is 45-55 years old, and gender is closely related to the incidence of RA, with a male-to-female ratio of about 1:3. RA is a chronic systemic inflammatory disease of unknown etiology, with chronic, symmetrical, polysynovial arthritis and extra-articular lesions as the main clinical manifestations, and belongs to autoimmune inflammatory disease. Patients often have hand or wrist pain and swelling (especially the swelling on the back of the wrist)...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K7/08A61K38/10A61P19/02A61P29/00
Inventor 邢将军许刘华彭立军任世阔华俊国曹铭刘加根刘明明汪士金施新华刘伟峰严明
Owner NANTONG CHENGXIN AMINO ACID
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap